Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Celine Mauquoi"'
Autor:
Celine Mauquoi, Riccardo C. Bonadonna, Gregory Bigot, Pierre Gourdy, Nick Freemantle, Alice Ciocca, Didac Mauricio, Dirk Müller-Wieland, Mireille Bonnemaire
Publikováno v:
Diabetes Therapy
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Diabetes therapy 13(1), 57-73 (2022). doi:10.1007/s13300-021-01179-8
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Diabetes therapy 13(1), 57-73 (2022). doi:10.1007/s13300-021-01179-8
Diabetes therapy 13(1), 57-73 (2022). doi:10.1007/s13300-021-01179-8
Published by Springer Healthcare Communications, New York, NY [u.a.]
Published by Springer Healthcare Communications, New York, NY [u.a.]
Autor:
Dirk Müller-Wieland, Nick Freemantle, Riccardo C. Bonadonna, Celine Mauquoi, Gregory Bigot, Mireille Bonnemaire, Pierre Gourdy, Didac Mauricio
Publikováno v:
Diabetes therapy : research, treatment and education of diabetes and related disorders.
Using pooled data from the REALI European database, we evaluated the impact of previous basal insulin (BI) type on real-life effectiveness and safety of switching to insulin glargine 300 U/ml (Gla-300) in people with suboptimally controlled type 2 di
Autor:
Didac Mauricio, Riccardo C. Bonadonna, Nick Freemantle, Dirk Müller-Wieland, Gregory Bigot, Mireille Bonnemaire, Pierre Gourdy, Celine Mauquoi, Alice Ciocca
Publikováno v:
Diabetes Therapy
Diabetes therapy 12(4), 1073-1097 (2021). doi:10.1007/s13300-021-01030-0
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Diabetes therapy 12(4), 1073-1097 (2021). doi:10.1007/s13300-021-01030-0
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Diabetes therapy 12(4), 1073-1097 (2021). doi:10.1007/s13300-021-01030-0
Published by Springer Healthcare Communications, New York, NY [u.a.]
Published by Springer Healthcare Communications, New York, NY [u.a.]
Autor:
DIRK MÜLLER-WIELAND, NICK FREEMANTLE, RICCARDO C. BONADONNA, CELINE MAUQUOI, GREGORY BIGOT, MIREILLE BONNEMAIRE, PIERRE GOURDY, DIDAC MAURICIO
Publikováno v:
Diabetes. 71
The effectiveness of Gla-300 in PWT2D switching from NPH is not widely documented. REALI database combines individual data from 14 European studies in T2D. We analyzed data from PWT2D uncontrolled on prior basal insulin (BI) , 1282 switching from NPH
Autor:
Celine Mauquoi, Gregory Bigot, Alice Ciocca, Mireille Bonnemaire, Pierre Gourdy, Didac Mauricio, Riccardo C. Bonadonna, Nick Freemantle, Dirk Müller-Wieland
Publikováno v:
Diabetes therapy 12(4), 1159-1174 (2021). doi:10.1007/s13300-021-01031-z
Diabetes Therapy
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Diabetes Therapy
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Diabetes therapy 12(4), 1159-1174 (2021). doi:10.1007/s13300-021-01031-z
Published by Springer Healthcare Communications, New York, NY [u.a.]
Published by Springer Healthcare Communications, New York, NY [u.a.]
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6aa0501073c0e6e465e6eedc45ebc90
https://publications.rwth-aachen.de/record/851238
https://publications.rwth-aachen.de/record/851238
Autor:
Riccardo C. Bonadonna, Didac Mauricio, Dirk Mueller-Wieland, Mireille Bonnemaire, Nick Freemantle, Celine Mauquoi, Gregory Bigot, Alice Ciocca, Pierre Gourdy, Mélissa Rollot
Publikováno v:
BMJ Open
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
IntroductionType 2 diabetes mellitus (T2DM) is a common and heterogeneous disease. Using advanced analytic approaches to explore real-world data may identify different disease characteristics, responses to treatment and progression patterns. Insulin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3163f90404e3259a37f6bb1ba805a9d
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5009
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5009
Autor:
Celine Mauquoi, Didac Mauricio, Mireille Bonnemaire, Pierre Gourdy, Dirk Müller-Wieland, Gregory Bigot, Nick Freemantle, Riccardo C. Bonadonna, Alice Ciocca
Publikováno v:
Diabetes. 68
Despite an increasing number of patients with type 2 diabetes (T2D) in the older population, clinical evidence for different therapeutic strategies in the elderly is poor. Therefore, we used the REALI pooled database, which includes a large number of
Autor:
Gregory Bigot, Alice Ciocca, Didac Mauricio, Mireille Bonnemaire, Nick Freemantle, Pierre Gourdy, Dirk Müller-Wieland, Riccardo C. Bonadonna, Celine Mauquoi
Publikováno v:
Diabetes. 68
Chronic kidney disease is common in patients with type 2 diabetes (T2D) and has an impact on the choice and dosage of T2D therapies, as well as on the individual’s glycemic target and the risk of hypoglycemia. We evaluated the impact of initiating
Autor:
Howard M. Gross, Erica Patocskai, André Robidoux, John W. Smith, Philip J. Stella, Jonathan Polikoff, Raymond S. Lord, Charles E. Geyer, Norman Wolmark, Bilal Ansari, Celine Mauquoi, Marc Buyse, George P. Keogh, Priya Rastogi, Eleftherios P. Mamounas, Sandra M. Swain, Samuel A. Jacobs, Alison Conlin
Publikováno v:
Clinical Breast Cancer. 17:48-54.e3
Background The purpose of this study was to determine the cardiac safety and clinical activity of trastuzumab and bevacizumab with docetaxel after epirubicin with cyclophosphamide (EC) in patients with HER2-positive locally advanced breast cancer (LA